-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 D70CtdBfqOwHBii5hZBwAb39UjaTlVj2RW6MGJsemspub2arqyhdMFuyU/z2O9Cn
 yg0w3HoENe4hvtFuB+hzSw==

<SEC-DOCUMENT>0001193125-10-285651.txt : 20110207
<SEC-HEADER>0001193125-10-285651.hdr.sgml : 20110207
<ACCEPTANCE-DATETIME>20101221165435
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-10-285651
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20101221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>Correspondence Letter</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g131831g78y46.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>8001 Arista Place, Suite 200 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO 80021 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phone: 720-940-2200, Fax: 720-208-9261
</I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">December&nbsp;21, 2010 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jim B.
Rosenberg </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Assistant Chief Accountant </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Division of Corporation Finance </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Securities and Exchange Commission </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">450 Fifth Street, N.W. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Washington, D.C. 20549
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Re:</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;ARCA biopharma, Inc. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;Form 10-K for Fiscal Year Ended December&nbsp;31, 2009 </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;Filed March&nbsp;4, 2010 </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;File No. 000-22873 </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dear
Mr.&nbsp;Rosenberg, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On behalf of ARCA biopharma, Inc. (&#147;ARCA&#148;), this letter responds to the comments of the Staff of the Securities
and Exchange Commission (the &#147;Commission&#148;) set forth in the letter dated December&nbsp;10, 2010 (&#147;Comment Letter&#148;) relating to the above-referenced Annual Report on Form 10-K. Set forth in italicized print below is the
Staff&#146;s comment, as set forth in the Comment Letter, followed by ARCA&#146;s response. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Form&nbsp;10-K for the Fiscal Year Ended
December&nbsp;31, 2009 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Item&nbsp;8. Financial Statements and Supplementary Data </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Consolidated Statement of Cash Flows, page 66 </U></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>1.</I></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Please tell us why your statement of cash flows reflects a $20.5 million change in accrued expenses and other liabilities, while the balance sheet appears to
indicate that the change in these accounts is substantially less. Similarly, please also address the change in your accounts payable. </I></FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ARCA&#146;s Response: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The difference between the change in accrued expenses and other liabilities
reflected on the statement of cash flows compared to the change indicated on the balance sheet is primarily caused by the accrued expenses and other liabilities that ARCA assumed in the merger with Nuvelo, Inc. on January&nbsp;27, 2009 (the
&#147;Merger&#148;) and the subsequent satisfaction of such liabilities prior to December&nbsp;31, 2009. As follows, ARCA has supplementally provided a roll-forward of the accrued expenses and other liabilities balances from December&nbsp;31, 2008
to December&nbsp;31, 2009. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">File No. 000-22873 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">(in thousands)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Accrued expenses and other liabilities</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances as of December&nbsp;31, 2008:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued compensation and employee benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,071</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses and other liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subtotal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,620</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liabilities assumed in the Merger: {a}</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued employee liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued facility exit costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unfavorable lease obligation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subtotal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,280</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in accrued expenses and other liabilities (net of amounts acquired and noncash items), as per the statement of cash
flows:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,454</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other roll-forward items, net: {b} </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(449</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances as of December&nbsp;31, 2009:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued compensation and employee benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses and other liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">756</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">997</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">{a}</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">See Note 2, <I>Merger with Nuvelo, Inc. on January&nbsp;27, 2009</I>, to ARCA&#146;s consolidated financial statements on Form 10-K for the year ended December&nbsp;31,
2009 for the acquisition consideration allocation as of the date of the Merger. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">{b}</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other roll-forward items, net includes, among other items, adjustments to reconcile net loss to net cash used in operating activities and certain noncash transactions.
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">File No. 000-22873 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The difference between the change in accounts payable reflected on the statement of cash flows compared
to the change indicated on the balance sheet is primarily caused by the accounts payable that ARCA assumed as a result of the Merger and the subsequent satisfaction of such liabilities prior to December&nbsp;31, 2009. As follows, ARCA has
supplementally provided a roll-forward of the accounts payable balance from December&nbsp;31, 2008 to December&nbsp;31, 2009. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">(in thousands)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Accounts Payable</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance as of December&nbsp;31, 2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">804</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable assumed in the Merger {a}</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in accounts payable (net of amounts acquired), as per the statement of cash flows</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance as of December&nbsp;31, 2009</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">{a}</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">See Note 2, <I>Merger with Nuvelo, Inc. on January&nbsp;27, 2009</I>, to ARCA&#146;s consolidated financial statements on Form 10-K for the year ended December&nbsp;31,
2009 for the acquisition consideration allocation as of the date of the Merger. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with responding to the Comment
Letter, we acknowledge that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA is responsible for the adequacy and accuracy of the disclosure in the filing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the
filing; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the
United States. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We trust this letter is fully responsive to the Comment Letter.&nbsp;Please do not hesitate to contact me if
you have any questions relative to this matter. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Very truly yours,</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>/s/ Patrick M. Wheeler</U></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick M. Wheeler,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief
Financial Officer</FONT></P></TD></TR></TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">cc:</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Brent D. Fassett, Cooley LLP </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Michael R. Bristow, President and Chief Executive Officer </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Christopher D. Ozeroff, Senior Vice President and General Counsel </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g131831g78y46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g131831g78y46.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`20"V`P$1``(1`0,1`?_$`+L```$$`P$!`0``````
M```````&!P@)`@0*`04#`0$!``$%`0$!`````````````0(#!08'"`D$"A``
M``8!`P,"`@8)`P('`````0(#!`4&!P`1""$2$Q0),15!82(R4A91<9&QPB-#
M@Q>!,PI"<J$D)4>G&"H1``$#`@0#`P@#"PT```````$``@,1!"$Q!09!$@=1
M81-Q@2(R0A0("2,D%I&AT5)B<H+2DQ48\+'!DK(S-&1TE%56-__:``P#`0`"
M$0,1`#\`[]Q,!0W$=@T1(2TY1QQ2%B-K?>:M772FW8TEII@T=B!B]Q3"U46!
MP4ABCN!A*`#^G7`-V]5>FFPY6V^\]>TG3+EU*1W%S%')B*@^&YW/0C$'EIWK
M=M/T'6M5:7Z;:W$[!Q8QSA]T"GWTD@Y&8(-]W+-%'?ITL#$>OZ.BGQUPS^)C
MX?<OMCM^O^LB_66Y'96[1GIUW^S=^!`\C<$!\<M44/UV!B'[U-/XF?A]_P"X
M[?\`]Y%^LI]BMV_\==_LW?@2PJN3<>7@ZB5/NU8LBZ7<*C:(F6+UT4I0[C'%
MJDL9QV%#XF[>WZ]<VVEU1Z<;]<Z/9>N:5J<S:U9;W,4KQ3,EC7%]!V\M.];;
MJ&AZQI0#M2M9X&GB]CFC[I%/OI;>0GX@USQ;4CR$_$&B(\A/Q!HB/(3\0:(C
MR$_$&B(\A/Q!HB/(3\0:(CR$_$&B(\A/Q!HB/(3\0:(CR$_$&B(\A/Q!HB/(
M3\0:(CR$_$&B(\A/Q!HB/(3\0:(CR$_$&B++<-M]^FV^_P!7QWT11UY394D,
M18AE[#!B4EBE'K.MU]P<I3E8R,J5P8\EXS`)5#Q[!LLJF!@$HJE+N`AN`^;/
MBOZN:CT:Z-WNY-"(;N6ZFCLK-Y`(BFN.:LU#@3#$R61@.!>U@<"*@\SV%M^'
M<>XXK*ZK[E&TRR`8<S64]&O#F<6@\:$T5(D17IJX/WLL]6>2KUPJ=W*/GBRK
MM^N98X>1X\<+&.LL!E#;&.(B!1$-]@VU\#].T3<>^]3GU*1\]YJ$C_$N)Y'.
MDF<7'&21SJN<"2`YU2&D@&@(7J:YO;32H&6S&MCA:*,:`&M%.``P'D4C:[A$
M7?Y9=@W$R$M(-XU02D^RE(-W;9)PB.P;`95LX26+O\04']`Z]-[:^'9MX[2K
M^5I++RYCA=0>K.R1C7M[N9CHY!W//8N#7N[C'X\8/I1L+O*T@D'S$$>9:\[A
M,6K6<?"W$J3!\>+;B8@`"D@LJO\`RPW#KZ9F@HH;]`]GZ0U^;</P\"SM=0U*
M%I:RWG=;LPIS3.<_#'\2-CWGL/)^,L[3=O/)%$3BYH<?S0!CYR0!Y^Q1ZDH6
M?I$FPF8YR^AI)JJF]BY!BLJSD6IDS=R3ULLD)%4B"8O0=]CAOT$N^O-UYINY
MNGVLV^J6\L]AJ\3Q);SQ.=%,RAJV1CFT<T5P!.#Q7!S:UYO;W5EJ]N^VF:R6
M!PY7M<`YI[01D?Z.XJ\'C?E!YEW$E=MDJ"?SY([R!L)TB`FDO+PZA4%7I$PV
M*G\P;'2<"4/LE,H(!T`-?T`_#!U7O>LO1O3=WZN&_:!ADM;PM%&NN+9W(Z0#
M(>,PLE+1@TO+1@`O*6]]`CVYN.;3H*^Z&DD=<2&/Q#?T35O>!5/KKT"N)+2D
MI*.A8V1F9=XWCHF(8O)25D':A46K"-CVZCM\]<JF^RDW:M43'.8>A2E$=$5'
M_M0>Y9-<T\X\Q*);IGSL&-T-DWC[%KH,VZT;A0[HM./`IF;H-E71HQ9E&R*I
ME?(MYYE;[784I2EFYM`"KS=%@F"Y`T?D!>*[$MN/.>83!%ICGKMR_DK%B:&R
MS#V5HJU!)K%/(Z4FH)U#IMG0>7U#585#`(E$H@`:*BG%<VN*O<(]US*G-]WP
M&_R?QZK.0(.^Y`I=CR)_ATLK#-&N.(^7EIFP,8LTVU-(IR$;$=[-N)6YC*."
M%4,0`,8*LZ-I56@YWB/=GX[XTL^9Z5R5P5R=#'D*_M5EQ#9>-J.-7D_7H=N=
M].#6)^JWYT[<2S".1473:*&1,Y!,2$.*HD3/%B.4X$)V?;2]R*D>X7C:?E&]
M>+C_`"UCM2);9'H`2)I5@FWFD5S0MNJDFJ@U</ZO.JL7!"D5(#EDX1,BKW!X
MUE2.;R^13NRGE/'N$\?6G*F5;5%TJ@4N,4EK'9)A4R;-@T(8B29")I$4<O7S
MURH1!LV0(HX<N%"))$,<Q2B6.:I8Q3S:YR>Y5;;,3A17*OQ<XLU6:<0+_D[E
MVJA?K_:G[43"K'4.@K/F=93E3LUTE5D51=DC0,7U#LJQBMA+,M#<\U+&5X/\
MJSPZZD![I'*!G<_`8S>3FJ#@25IXOP+N07-/9X]BG`1YE?BDG(%4`@[`<1#<
M2E1V8*)G%?D![D&,?</@^&_-ZX4^^T:ZXOR-9\69!K5"@:^RR&O3R14BWEHV
M9B&C!=%]'1B;M.2BW")5VRIR&$3I&155*D-+:C-7T:+!-SE_*-6PCBK(F8+N
M[(SJ>-*=/W2=6.H1(QV,!'+OS,T#'^R9Y(*(E;H$ZB=94I0`1$`T5`J:!57^
MR]SMNG-7"N5@RY-I2N6\<96FG3\H),FQR8\R,Y>6>A-D462+9,[*M'+(0B)^
MP3BA&I"H8RAA,8JX4*N6T6*W/Z7]O^'1%!WG\GY<0UE,0[@-DB%W#J&X!"6/
M<-PZAOKY_P#S'!7HEI@I6NYK84[:VMYAW+M;I`XMW'.1G[D_^W&HMX2J+)95
M@YCI=I$2Q#E%!";)V,EQ,4""@$@FFLU.1P4QB'3<II)F*/:)AWUY.^'O8^GD
M6U[IEY%9:T7>@V[%(G5`!;XP#HR'@EKF3,C86DM+G5HN;[LU.8<\<\;I+>F)
M8?2'?RX$4P(+22#C12_).05<G3TZ!K[5>80?0LY+LW#P5H:L6%NB*I&T6LU.
M*[SS-URG.05`(DF8I!$P@(%]L?:#;VU]>=LK0--ADUR.YM;JXB?(76MA>,;S
MAD#HSSR<S'M<YI>&QL<UA<XU#.M3:W=Y:?O*[F<VV+'L80VCY8R:5<#@*$$`
MTJ2"<,RO9*LLY9HV;2$"T]<D:6FHV**Y!&&EYF2%)99S)K.3@L1)HDEWBEW]
MJB9!)N'P'L+5-JV>L6<-IJ6G0C46FYNH+<2<MM<W,Y:Y[YW2'F#8FMYO#YN5
M\;2RH'HG:H;Z2WD<^&5W@D,8YU*O8QM0`T#"IRK3`D%5\YKJ3!NJ_</9=O-R
MJBISN/E)1,R(H`&`2FDE2))&!'M`I2-TCI%(``4X``!KYM?$'LK36"XO[^]C
MO];#R9/=A6(''`SN:UIY:!H;#&Y@:*->`,.X]IZE*>2.-ABMZ8<_K4_-!)Q[
M7$'M"EGP/3!+"4BGMMVY#LNQ=]]@]%"B`!OUV#7L_P"7=_X!-A0?:.^P[/H[
M;!=?=7#7=3#_`).+^=ZFCKW:NKU6G[H-WG5\+TGBU09!5CE#F]DR!X[0+AHH
MH1["T*8,$IFJW%%/[1&D#C5F\24/T[%'J?7?14=JH=SK`PGM:>]/B#(-48(U
M/`N565.[F#,@)Q3"B76.0Q3D-CXR=B7;6[+%HSABCL)1,F;IN`ZJS'I-[UV'
M=/H$#!\0,'P,`]0,`]0$!#J&HM->A\0_6'[]$7'EQ6#_`/1KE78/_=[D^/\`
M\=63<=7@M0^HNJWD'D*J8FP7E[)-ZD&<74Z=CJW3,RZD%4T6YT$(1X5)@051
M*59W*.E$VS=$-SKKK$3*`F,`#%@,US3?\;3`61HR2S?R6F8E["8TL]-A,6TQ
M9\BJW)<9IE8"6&PRD,4Y0!W$5<&:33U1=TE'+I5-,PF15`M*S>>"3_\`R&,_
M6Z_YLP9PAI3]8D2BTK5[M$8B<Y49[(V09UW4\<,Y),H@5PWK4>BLZ3(/V?+)
M`<0[DR"`(P4%5TY\><(5#C;A'&6#*,S0:5S&U2BZZ@=%/QFE))!$%IZP/-_M
M*R5CG%G#YR<>IUW!AU%@34U3RZ*)L;IA^AW^[8DR+98M=Q<,'V*Q6;'4PT?N
M6*T4^ME2E:38FKHK<Y"243+0<N<%FJW<D99%%7;O2((%:TP3G:**K;W`I$<T
MY9XC\"XL_J6V;\E-\SYW9D.;QI<<N/;YC<I>)E2@00*RR%?6\5%)]WV50(L0
M0$-PT60P!*I8XMN`]NOWRLF8&<=L+BGD'.2U3KS4H=L<C"Y3.3(^&CMBCV)`
M6#M)E*Z0P?[8K*E#Z0U5D?2;5=>&HM-;G]+^W_#HBA+ST6!OB>KJ"5,X!D>&
MZ*D`Y.L)8OO%-T';7@3YBLWN_1?2YJ,=R[GM<'`.'^%O<P<%VITC;S;AN&XC
MZB_+#VXTRN$9I1-!DLZ;4>(8]I!,^FX1D=4Z8_\`4V9%`\B],.P["1/LW^)@
MUTQT`UV4:=;7%U#H-E8!HK+=6L1);VLB`,TIPP+&<M<W-&*W[==JTRO9&ZZE
MEQ]&-Y&/>?5'G->Y?A?'\KC#*D[9WZ#HU.O+\EDK-D,S7;1JQ7K='U$<J8Y=
MF#EFX2.":2@E$R'88G<4=]?AZA:EJO27J[J.Z=6CF^PFXKD7]A?F)[(#XK&^
M)`\D?0OC>UW)&_E+H?#>SF::C5TJ&#7]O0V,!;^]+1GA2Q5!<.4FCA^,'`BI
M%:.J#0I^J'?7E[>(S0>7\K5INN[E)HS-=Y'$,+=1!!H!"%_\_P!RK@IEB)B/
M8B!A-VAMOZ*Z==0+WJ%>Q[A#G'9^E1ODGNO#?+"/HRQL8#1]+Z3PZ1K"0V(.
M+Z`BO$-7TF/28S:FGO\`,0&LJ&NS!)_)P&!.9I2J8/.$RJ9!\J@TI4HR[3]C
M^#AF1>U/?8#.&HE(_8FZAOY4P#?X&-\=>=OB"UZ7]VW-Q!#H-Y8D&DMK;1##
MM?&0)HCC[;`*Y.*Y?M2U'C,:]UU'+7U7O=GW'U7>8^9/OP75!;#,HJ!2$[LA
M6/HF0"$#9C"?=*7H&^O0WR\Y?&Z"3R\K6\VX[XT:.4?W=MD!@%Q;JTWEW0QN
M)I919^5ZF4'7H'Q'7NE=8JA:0E^1G*;W,\HY>XUQ>%;'3>!U86XXUIQFN;O,
M55E<MY$:IS67)VL?DF*EEWMB@6+9*$<&5[$DD-MA$QP[:L\`VAS*A_[W&`^:
M63>/-=SEG6I<96L1@";4!Q)X/G\G2=N3KF1G<177X22%R@(Z/&OL9Q&/74.1
M;S(G^T4O:*@Z*M+:T%5=1[7G(X.47"#"&1'SXKVWPE?#&F0Q[Q.N2ZX\!.O2
M#EV)A$?43D<W:R?UD>E'Z=18.%"K`@^(?K#]^BBXKL68]4RE[_F:Z2C?<B8R
M5E,R<CET[IBJP(5>\11XZD3SX$XN9<QTLW1;O_!X'29VZA5FYSD';??5X+5]
MA;ON35GD%PTY:X3>\I,DY3YO<.92Q,+=7:EF"?=KP-E90JI$;C1[)`0)H:I.
M[]3TGB<C&.#M`0>E,W,=(2@Z2`C:$88%=?F'[9C2]XLQ]<L-+P#C%-DJ<-+4
M`]69M(V`3K#MFFI&-8Z,8HMVT4FR1'PG:%33%JJ0R1B%,02A%IFH..:X\_>7
M;N,4>[IB_*EG2.E5)!KQFR*U=J@/ISP=$N"<38P3.("408+5E4Z@?]/D`1#K
MUJU&^JNU%-9%RFFY;JIKMW!"+H+I'*HDL@L4%4E4E"")3IJ)F`Q1`=A`=1:2
MRT1>@`CT`!$?T!UT1>=/I$``.HB([``!U$1'Z``.HZ(N?KC=,<M.2W*[E9SS
MXYPO'F?Q_)SRO$_#<EG&PY(BU2XQPS)`K/SM(;4N%E$%(6]WERJ\767.0YED
M/&0.TAA$LS0``JO+WO,/\PX25P=S,R]"8%K<Y3YB)QE'V'`<YD&2<-)B/DI'
M(6/I*U?G2&B1;A'2[!\FT5;G.(J+`FIL`IZH5:1D,EU-<7LXP_)7COAO/$&*
M0-,G4&!LCMLCOV1L^HU!I:87J(CY(.RM7;0^_7N1'46!%#12$_I?V_X=%%";
MGW&OG>$&3]FD=1."O,!)/SD`P^G:*M9:,*X.)?NIE>2")1$?AWAKPC\P_2K^
M_P"@T-_9L<^&PUZTFF(!/)&Z.X@#S3("6:,$Y#F7:?2&>&+=3H92`Z:UD:WO
M<"Q]/ZK7'S*N#&%]:Q#E-Q(E!X9$Q3(LUS"*3EP782&?&[@.=FF;J8@"!E=N
MW<"B(Z^6_2/J/;[7O@_6OK#&NJR-Y);(\8@RFM?#;FYH-9#1F#>9P[HW#HK[
MJ,L@]$',C,#CR_E'MX9T."G56,S`JTBDI1XE).K38XUW,@\3070""8.4V31A
MZ50AFZ:#A8ZY@(4@%*FF0`#8=?1+:76]MQ9V<>IW$=W<:OJ<$MR)>1S?=(I!
M%'#X;@6-8YYE(:T!H8Q@``*ZAO\`;19+(Z%I8R"%P92H/.X<Q=7.H%,:UJ37
M)?A9,T&+&NCQSQ)@\K,Y)"Q*W(@FV6KTLN=%5@HS(4&R[5JZ33*9,Q1*9)?8
M?NZT-T]<S#I<DEC<1VU[I%_.8@P,#'65P\M="Z(`1NCCD:QI86EICEH1Z(*R
MLML%\[1*POCN(F\Q-21(P5#@<P2*XUP+>]06R;>VTJZ46C`]&"QS"9FDH82M
M%A_W"M%!$5!9G$1$@"/>F'V!$=@,/SLZM=0[?<U^7:)]!"YQYHVDTB=Q$;JU
M,3L2P$\S!Z#BX`.=V]M[1WVL8;<>D1Q/$<*]_;P.?%66\%HQ\PP*U=O4CI%G
M;;99AB*@"`KLC*-(Y-P7?;N357CE.T?@(!N&OK)\O[2;[3/AX@N;UCF1W^KW
MMS$37THB8X0\5X.?"\@Y$4(S71O5FXAFW>Z.(@^#;Q,=W.`+B/,'!:/.OF?C
M7A=@&_Y*LUHKR=Z;P$@QQC1EI1@-AN%]?LSH5M@RA3+^N7CVKY9-R_7\?C;,
MDU%##]T!]M+K4"IHH\>S#!4N$X%XLE82Y0=UO.5'ULS)E^782[*1E7&2[U/N
MWE@0G445E'C23A4$FS%9-8`,4[<?Q!N5?6O<IW<CJ7C_`"7@K+.,LGS4!`4O
M(6/K;4YF6LDBPBXV,;RL*[0"7.[D5V[=$T(N8CLIQ,`)F1`PB&VB@K7!<G'L
M(\W\?\>,C92XT9COL)6J9E63CY['UNFI1O'TYODF!*M`2C%Q+O%D6$4C?8)-
MJ=FNL8B*J[`B7<"BR8&JU'BHJ%V)/[?48B&_,DM:JU%UT$CN!GY&>BF4(#=$
MIE%E_FKEVFQ\*29!,8WDV*`"(ZBTEQ:<7\_8;9>_3<LS/\BU5ABFV9KY!LH#
M(3Z89LZB_P#S/4[-`5IZ6<<JI,$HN?E?&DU<G.5%05TQ`W:<!U5J'U%U)\Y^
M*=&YY<7KGB-20A%IAVA^9L479NNWD6U6R1"H+J5V53>LE%@&,?&5.PD2$$PJ
M1[M8`#N[1"+`$M*YW_9AY_\`_P!2[U?."7+N>3QI66%MGV]&E;R]3C8S%>46
M,FNTNN.Y^4?G2;PU;L[Y,SQBX5.1HC(E5Z]KXABU9N%14*VOW:N`K+W",#0-
MOPP_K<SFW$H2LGCMVVE8Y:&O]9F4&ZMEQTYG&RRK-NM+^D;NXMPHIX$7R($.
M)$G*JI8L6FA[DT7M1>Y/"S]0@N%_+9^YP]RHPRU;T&.893(-0=Y(K\&0K"`0
M!2=]&!,@0\<BFT=LU1!62*D1XV,MY52I55S>(R5\ZZR#9NH[<KH-VB20K*NE
MUDDFR:)2]PJJ.%#E2(D!>O<(@&VHL%0OS+]Q&D9MY*<<?;WXOY#"QS>1L]XZ
M#/V2<>SQOEU=H5.L+>XV/'E:L\*Y*:0G9MC7%?FZS)846;!,[4YS*.%2(U9A
MN%2I$>[QSKIG$_BGDV$KUUA0S[E"ORU`QG5(Z59.+/&KV!NK&SMV=1S=P9]%
MQM3A5UUDW*A"E-(>G1*(G/TBC14]RDW[?5'QIC#AGQSQYBJRUVV5NN8IJB[B
M=KDJQEFDO8+`Q+8;1,G79+*B"DM9I-VL(*;'*)NPW4H@!'5)Q2%]TF@X^RAP
M0Y)4V_66LU8J6-Y>ZUB6LDI'QJ;*XT`"6ZJ*M3OET3&7>S40DS`$^XZA7)DR
M@(G[1(W-4R?\?3G7CJ$QW:>(&5KU"U&>86QY>,+&M<NTB6$]$6M-):U4F*?R
M+A!H$Y%61%2019=P*N4Y%44BF\*@!2LGMXA=4?JFOH?6>I;^C]+ZCU?G2]+Z
M?Q>3S^H[_#X.S[7?W=O;UWVU%IKY]CA(FRPDE7YY@WDX:9:+QTG'NB=Z#IHY
M3,FJD<.@E'8=RF`0,0P`8H@(`.MHU_0-'W3HEUMS<%O'=Z)>P/AGAD%6R1O!
M:YIXC`U!%'-(#FD$`K]%I=7-C<QWEH]T=S$X.:X9@C$'^6!R."K%N7M[S24L
MLZQM?(PL0JH8[>-MJ#U)_'D,<PE;A*1B+I.132*(`!SHI*#MUW'KKY6;\^6O
MJYU:2?IGK]J-#>XED&HME$T()-&">!KQ,&B@#G1,<?:J<3WKIG6:V=;B/7+1
MYN0,70EO*X]O(XCEKV!Q'D"T6G"C.315!4MSH`B@*`D`'E@*``W[?&4O_H@]
MH`!-;%9_`#U\L9XYX-P;?!C+*#GO,!'3E`^K=P6K+U2VG*TM-K>4=7V8^/Z:
MQ=<)<XNC*F-=*!_.!8JF[VP#W%6$1,4P?)0`>H[_`*P`=:=U\O\`Z]WCWOGW
M!M\B0.#ASWE"'UJ#]6[_`+M#P5BZI[4B`'NMYA3A'P_37UJ1[?$D:61>9-O,
M>XB$E2J+P]21>B[D2E.43-U9>12:_+T%2[@8R2)U=ONF*/4.4=/OELZA'J\=
MWU0UVVDT6-P<ZVT]LOB3@$58ZXF##$TXAQ9$Y]/5<TXC\VJ]98?=S%H5H]MP
M10/F+:-[PQM>8]Q<!V@JR^)BHV"C(^%AV3>.BHIFWCXY@U(";=FR:IE1;MT2
M!\")IE`.NXC\1$1U]4='T?2]OZ5;:'HL$=MI%I"R&&*,<K(XHVAK&-'8UH`[
M3F<5T7<7$UW.^YN7%]Q(XN<XXDN)J2?*4P-MX><4<@7*:R'>^-^%+M>K$+<\
M[;;;C>K6*?E!:,VT>V,]DI>-=N%`09-$DB[CL!$RA]&MR6E4KZ.,>+W&?$%E
M=7W#N"\1XXM,M$KP[NSX_I-=K<A(0KQPT=N&"CV#9M@78N'#!$YB[B43)%'Z
M-$))S2@RUQ_PCGMI!L<V8EH.5V%8=O'U?9WZL1EG9P[V012;/G+!O*MW"""S
MM!$A%!`/M`4/T:*5(R36+<#>$;AJ9DMQ%XX*-C$!,R0X<H8`8@?`HF"$`XA_
MKHK4]J^U)<,^)DS1:KC"7XX8:E,=4>5F)NGT:0H4`\JM;E[`HJK.2,/!KLU(
M]DZE5%C&6,0@=XCUT2I7QE.!_"19L+-7B-QP.V,F"1DAPW0]A3#IVB8(/NVV
M^O1*E/1C#$6*L&U56G8BQ_3\7TPLD_GEJ]3(5A7(`DH_(B$C*'8L$D&B2[A)
MHF"BFP;E3#?H&BE:YIN+9Q`XG9"M<Y?[QQNP;=;E:A:K6"V6;&E1L$U.F;,6
M\>U7D).1BW2[PY(]JDF50QA$4R%#<0`-%:D)P<5X6Q%@V#?UC#6-*3BVN2DN
MK/2,#1*[&UF(=S2[1HQ6DUH^+0;M1>*,V**8G[0$2)E#Z-%*DYI'9PXJ\;N2
MC(C'/&$L=91\*!6S21M%;9.;!'MRJ"J5"+L[<C:QQ:0*B)MF[I,-^NBH)&2C
M27VH>!9FY(U[A:5F*^@)?25*=R_FJ:I[,"&[BIMJO)9"<0I40^'89$Q-NFVV
MBO,Y28QGQ4XR89<1KW%''S#6/9.'`P1<U5<<U2)GF(J-E&:AV\\WBRS":BK1
M8Z9S>?N.0Y@,(@8=%*DI,R'"+AQ,3T_:9GBU@.:LMJEGT[9)^:Q93Y>8FYB3
M=+/I"2DI"1BG+IT[>/'!U%#F,(F.81T2I2[Q1QSP'@EU87N%L-XWQ2YMA&"=
ME5Q_48:K?/"1:CQ6.+)$B&K5-R#)207,GW!]D53?IT2I.:T\J\8^.N<YF&L6
M9\(8ORI.5U@I%04G?J;"6EW$QJSKURK)B>7:.@0;G>?S1*4-N\=]%*E-^^X$
M\(9%N+5[Q$XX+("(")/\.T5/J7[H]R4*0X"'Z]%:GM4@/\4XU_Q?_AK\C5G_
M`!1^4OR/_CSY4U_*7Y.^7_+/RS\F[/2?)OEW\CP=O9X_L[;:*=_%+U?[@?\`
M<'[AT1:NB(T1&B(T1&B**O+>1;+T2O4$LD,3*Y'N$5"-Y7YJZB$X.#8":3MU
MA>NFSEJ08Z,@DE"JE7$R'\X!,7<`T63<Z]B>/%USQY<:RFEC.40DZ[5%4JB5
M-%H]8^@4B&;9-!IZ9^V:./'Z,4S$.!.Q0IMP$>NBA!&:3<<_Q]=LQJR,%>IM
M_;<;5IQ$3-5BY)\2H"UL+I4$WTBV%L6,E)1LJW.0ITECBF8I0,'<0-B9!*JT
MY4H=,?FB[!.@VD$([YS(MF;"2E3P<'Y`1&>L1HMH[)7X0%1V]2[%%(=A$!$"
MF$"4.:5DM.0\%$/)^7DF;"&8,SOW4BX<HI-"-")^4%2KG.5(X*DV[-C?;$0`
M-]PT43'X5Y!0.5F<6TDFX56YS;&4L$75'3::2,^JK>16;L)6.DI2,8,9DZC$
M$UG`,SK$2%3;<0*(@61;3R)$\M#1DTQQ9CQZ^-&_G2_H*R[\TJXC&4=1:TT/
M+W9[)@FZ;-%V(QQ")&!R!T@[Q$``VPZ(WB>Y/]0\DT3(:,N6CRY)%.L/DX65
M:&CI&)<1:_@!1HBHPE&;)R1NLV+NB<"=ARE'8>@Z*$$9K?MM]IU%9JOK98&$
M*@DS<R!BN#G4="Q9@`NGA&;<BKHS5`Q@*97L\93F*43`)@`2BP1OM6/2&>1'
M,@>*J;V&:SR3^7:.H]<L<^2(LS,I'K)>N!TZ(H7QH`F*RAC%*4HB(!HE,:<4
ME:[G;$]KFZO7*_<&DE-W&%6GZ_'ILY(BSF-005=*&<F59D2CG7I4#J@@X,FL
M9,O<!>TQ1,5H5]FP97QW5;)'5&PVN.B[!)M'SYLQ7\XD2:QS(TBY5?O$D3LX
MT?1D[TRKJ)G5`0[`'N+N2A*1Y^2>$TX0UA4NZ"<8G.N*XOY8B>3?M91JNU;N
M`>Q1XPLDQ9(JO40,Y6230`RA2]W>/;HE#6G%/D&P@`@("`@!@,`AL)1#N`P#
M\-A#KHHFW;9;Q^_N$/1(NP)2]DFVDK(,V\2V=/V9(^&)N]?N91!$T<BR!8!1
M35!0Q%'!13*(G`0T5IA5.1HHMS^E_;_AT18K_<#_`+@_<.B+5T1&B(T1&B(T
M108N$U4Y[D_+.+R1Q(IX=JT$QQY06S1=]*W:X6Q,\N[DHV)`@A(I,B(HH@<P
ME;(JE(JL8A$Q$*L\F^5/ECZNJXRH5[M]^*B$]:)&TY/R"WC#"Z;QYG+,RHU^
M/52[1=IPT(R3:^0O^\L!SAT,&HL3B:!(KB8V2DJI/Y$<QJC68R1,HS;E8C3T
MD4P@VB:D?5Z;`E/V**Q]2A$4DE#E3*@+E90I#J"0X@*KLZ<`F"1-,R^-,KT]
MJ@>3SWR"R9<*[+1H]QWM:J\5,#!&?SP[&^2U>OU9`YFQE>PBPNB`B!Q-JK+B
M#[(3W<H'+&JX-@<;INFWKKA(5#&,3)/TTC&8-!309SMB$52G!L+"OMEQ.MT%
M(%M]PZCJ+%HJ:\%^]<K;.W9VI]BJ10-C7!&/G](B9IOVFCIVU3"*4<O%PSD@
M^.28UZ#;D]2ND)D2NC`D`B8IP*0Y8YE)*V25*EN1,K?LER:,70,,-ZYCRN&?
MMWJL9*9,MI%+$\,LF@V<%63B6940W.`(@X(F8P[D#1!6E!F4YV.(MW1X7-N9
M9^->I/;U.3N04X$R9DY-O4:S#JMJJP=-^P5&\M(QC,SA1(P=Z)G($,`'(8-$
M.)`439G(*=\J6-:L3YI*27(::3E,MV]M$O\`RNHJ#%M*/<4TE!9NFNZ1C45$
M8I,$=FB9C&,=0RB[E0E65*5/8I;<DWSIAB`8.O0Y!MEO?0E`HT?X$E3Q$W:$
ME(4ZR!T?*DT/#U]P\`5TS=J90$0-L.^HL6Y]R<W&>.(+&-+K5-AVZ"H5]@5`
M\D=!,7CZ2723+*R1UC%%4JD@L3X`.Q4BD3#[)"@!0XFJAE9'\6_NN3N0KF(!
M[6,2/'U&Q#`)-#B%SRW(.D&LM9EVP%[WV]D70:H*&W`2-RG`0].38LOR4G(_
M'[>MV;&&#ITCVP6BR/T\Z9U7:H'>/+?-HR)U:W44W!Q3;E@&,Z=5T].LJ1N5
M%J941\B@$$E?:X*3&=[XPC[=C+%\PO),Z]?G$Y(692*92#M_8(ROHMP84.-+
M')J.N^W2[M))SV=HBS(=+N*543!5&C`GBD7QOL!\DY#R=DV0AW#!9$_^-ZK&
M)-R$BZ12ZF\#QPAW!13:GF;!*K'<*I-04(D1MN82$,B!Q1V&"F9J+%;G]+^W
M_#HB%2B8H`'QWW_\!T1?AX3_`%?MT1'A/]7[=$1X3_5^W1$>$_U?MT1'A/\`
M5^W1%AZ4/+Y_$EY^SQ^?L)YO'OOX_+V^3Q[_`$;[:(LA0,8!*8I3%,`E,4VQ
MBF*(;"4Q1`0,40'80'H.B(!`Q2E*4I"E(4"D*78I2%*&Q2E*4`*4I0^`!T#1
M%B5H4JBBQ4D2*K`0JRQ2$*JJ5,-B`JH4H'4`@?`!$=OHT11SF:;D"T9]I%PF
M:PP+CV@Q%F80@?F%DY?JV*P@FS6M#J*%J0A&B<0F**:(*G7*8_</T@!6HIWJ
M1I&WB(1))--)),H%322*5--,H?`I$R`4A"A^@`#11>&:@<-CI)'#O*IL<A#!
MY""!B*;&*(>0AB@(&^("&B+,43CON`#ON`@(@("`_$!`?B`Z(OS*T*7Q=J*)
M?`42(=J:9?`4P=IBH[%#PE,7H(%V`0T19^`P[;@4=AW#?8=AVVW#<.@[#HB]
M\)_J_;HB\\`]`[$]@'<`[2]H#OW=P%VV`W=UW^._71%YZ;[8J>-/RB0$Q5[2
M^04P'N!,5-N\4P-U[=]M^NB(%ON8AQ(F)T^[QG$I1.GWAVG\9Q`3$[R]!V$-
MP^.B((V\9>U,B:9>XQNU,I2%[CB)CF[2@`=QS#N(_$1^.B++PG^K]NB+8V'Q
M]OT]FW^NVVB+/1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$
*:(C1$:(C1%__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
